Tango Therapeutics (TNGX) Non-Current Deffered Revenue: 2020-2025
Historic Non-Current Deffered Revenue for Tango Therapeutics (TNGX) over the last 4 years, with Jun 2025 value amounting to $30.4 million.
- Tango Therapeutics' Non-Current Deffered Revenue fell 44.09% to $30.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $30.4 million, marking a year-over-year decrease of 44.09%. This contributed to the annual value of $44.8 million for FY2024, which is 32.87% down from last year.
- As of Q2 2025, Tango Therapeutics' Non-Current Deffered Revenue stood at $30.4 million, which was down 18.86% from $37.5 million recorded in Q1 2025.
- Over the past 5 years, Tango Therapeutics' Non-Current Deffered Revenue peaked at $116.6 million during Q3 2021, and registered a low of $5.8 million during Q1 2021.
- Over the past 3 years, Tango Therapeutics' median Non-Current Deffered Revenue value was $58.6 million (recorded in 2024), while the average stood at $57.7 million.
- In the last 5 years, Tango Therapeutics' Non-Current Deffered Revenue skyrocketed by 1,898.70% in 2021 and then slumped by 44.09% in 2025.
- Quarterly analysis of 5 years shows Tango Therapeutics' Non-Current Deffered Revenue stood at $114.7 million in 2021, then dropped by 19.73% to $92.1 million in 2022, then dropped by 27.59% to $66.7 million in 2023, then plummeted by 32.87% to $44.8 million in 2024, then crashed by 44.09% to $30.4 million in 2025.
- Its Non-Current Deffered Revenue was $30.4 million in Q2 2025, compared to $37.5 million in Q1 2025 and $44.8 million in Q4 2024.